Previous studies indicate differences in experiences of loneliness during the COVID-19 pandemic but are constricted by limited timeframes and absence of key risk factors. This study explores temporal and inter-individual variations of loneliness in Canadians over the pandemic's first year (April 2020-2021), by identifying loneliness trajectories. It then seeks to provide information about groups overrepresented in high and persistent loneliness trajectories by examining their associations with risk factors: social isolation indicators (living alone, adherence to health measures limiting in-person contacts, and online contacts), young adultood, and the interactions between these factors. Data comes from a large longitudinal study with a representative Canadian sample (n = 1763) and 11 measurement times. Analyses consist of (1) a group-based modelling approach to identify trajectories of loneliness and (2) multinomial logistic regressions to test associations between risk factors and trajectory membership. Varied experiences of loneliness during the pandemic were revealed as five trajectories were identified: moderate-unstable (38.5%), high-stable (26.7%), low-unstable (20.5%), very low-stable (8.6%), and very high-decreasing (5.7%). Individuals living alone associated with higher trajectories. Contrary to our expectations, adhering to social distancing measures and having fewer online contacts associated with lower trajectories. Age and interactions were not significant in regard to loneliness trajectories.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696544 | PMC |
http://dx.doi.org/10.1038/s41598-024-81519-3 | DOI Listing |
Gastric Cancer
January 2025
Department of Medical Oncology, Hospital Clinico Universitario, INCLIVA, Biomedical Research Institute, University of Valencia, Avenida Menendez Pelayo nro 4 accesorio, Valencia, Spain.
Introduction: Gastric cancer (GC) burden is currently evolving with regional differences associated with complex behavioural, environmental, and genetic risk factors. The LEGACy study is a Horizon 2020-funded multi-institutional research project conducted prospectively to provide comprehensive data on the tumour biological characteristics of gastroesophageal cancer from European and LATAM countries.
Material And Methods: Treatment-naïve advanced gastroesophageal adenocarcinoma patients were prospectively recruited in seven European and LATAM countries.
Breast Cancer Res Treat
January 2025
Division of Medical Oncology, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Purpose: There is an increasing incidence of young breast cancer (YBC) patients with uncertainty surrounding the factors and patterns that are contributing.
Methods: We obtained characteristics and survival data from 206,156 YBC patients (≤ 40 years of age) diagnosed between 2005 and 2019 from the National Cancer Database (NCDB). Patients were subdivided into two comparison groups based on year of diagnosis (2005-2009, Old vs.
Am J Sports Med
January 2025
Department of Pharmacology and Biostatistics, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Background: Patellar instability is frequently encountered by orthopaedic surgeons. One of the major risk factors of this condition is underlying trochlear dysplasia (TD). Recent trends have indicated the use of multiple procedures to correct patellar instability under these conditions.
View Article and Find Full Text PDFClin Exp Nephrol
January 2025
Division of Nephrology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-Ku, Saitama, Saitama, 330-8777, Japan.
CNS Drugs
January 2025
Department of Cardiology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Background: Early neurological deterioration (END) is associated with a poor prognosis in acute ischemic stroke (AIS). Effectively lowering low-density lipoprotein cholesterol (LDL-C) can improve the stability of atherosclerotic plaque and reduce post-stroke inflammation, which may be an effective means to lower the incidence of END. The objective of this study was to determine the preventive effects of evolocumab on END in patients with non-cardiogenic AIS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!